Applied DNA and EvviVax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA™ Platform as a Novel Cancer Vaccine Strategy in the Journal of Experimental & Clinical Cancer Research

STONY BROOK, N.Y. and ROME, Italy–(BUSINESS WIRE)–Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and its program development partner, EvviVax, S.R.L. (“EvviVax”), today…